March 14, 2025
Article: GLP-1s Reshape Key Service Lines: What to Know
Blockbuster GLP-1 medications like Ozempic and Wegovy are transforming patient care, altering surgery volumes and redefining the healthcare industry’s financial landscape.
The obesity drug market could reach $200 billion by 2031, according to industry projections. Perhaps unsurprisingly, some health systems and industry disruptors are expanding weight loss programs in response to the growing demand for GLP-1s.
Beyond weight loss programs, GLP-1 medications are influencing multiple hospital and ambulatory surgery center service lines. In healthcare C-suits, this trend in influencing long-term operational and financial decisions, especially as GLP-1 medicines affect elective surgery volumes.
Elective surgeries are a substantial revenue source for hospitals and ASCs, and several procedures could rapidly decline in volume over the next few years.
Click Here to Read Entire Article